Navigation Links
FDA Authorizes Emergency Use of Intravenous Antiviral Peramivir for 2009 H1N1 Influenza for Certain Patients, Settings
Date:10/24/2009

SILVER SPRING, Md., Oct. 23 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration announced today that, in response to a request from the U.S. Centers for Disease Control and Prevention, it has issued an emergency use authorization (EUA) for the investigational antiviral drug peramivir intravenous (IV) in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Specifically, IV peramivir is authorized only for hospitalized adult and pediatric patients for whom therapy with an IV drug is clinically appropriate, based on one or more of the following reasons:

  1. The patient is not responding to either oral or inhaled antiviral therapy, or
  2. When drug delivery by a route other than an intravenous route -- e.g., enteral (absorbed by the intestines) or inhaled -- is not expected to be dependable or feasible;
  3. For adults only, when the clinician judges IV therapy is appropriate due to other circumstances.

The FDA has reviewed the available scientific data and has concluded that the criteria for authorizing the emergency use of IV peramivir have been met.

There are no FDA-approved intravenously administered antivirals for the treatment of influenza. Peramivir is the only intravenously administered influenza treatment currently authorized for use under EUA for 2009 H1N1 infections.

The EUA authority allows the FDA, based on the evaluation of available data, to authorize the use of unapproved or uncleared medical products or unapproved or uncleared uses of approved or cleared medical products following a determination and declaration of emergency, provided certain criteria are met. The authorization will end when the declaration of emergency is terminated or the authorization is revoked by the agency.

For more information, see http://emergency.cdc.gov/h1n1antivirals or call 1-800-CDC-INFO (1-800-232-4636).

Media Inquires: Patricia El-Hinnawy, 301-796-4763; patricia.el-hinnawy@fda.hhs.gov

Consumer Inquiries: 800-INFO-FDA

SOURCE U.S. Food and Drug Administration


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Authorizes Share Repurchase Program
2. Syndication Inc. Board of Directors Authorizes the CEO to Rescind 300 Million Shares of the Companys Common Stock to Treasury
3. Quest Diagnostics Board Authorizes $500 Million in Share Repurchases
4. BD Board Declares Dividend Increase and Authorizes Additional Share Repurchases
5. Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program
6. Young Innovations, Inc. Board of Directors Declares Quarterly Dividend, Authorizes Share Repurchase Program and Announces Election of New Officers
7. Brookdale Board of Directors Authorizes $150 Million Share Repurchase Program
8. Varian, Inc. Board Authorizes New $100 Million Stock Repurchase Program
9. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
10. Aflac Incorporated to Accelerate Share Repurchase in 2008; Authorizes Additional Share Repurchase and Increases Quarterly Cash Dividend 17.1%
11. QLT Board authorizes exploration of strategic alternatives to enhance near- to mid-term shareholder value
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. Justin Kolnick, Kara Diamond, ... teaching their patients about the key role this treatment plays in protecting oral health, ... endodontist. To better serve those who need a root canal in White Plains, NY ...
(Date:3/27/2017)... ... March 27, 2017 , ... SyncDog, Inc. , the ... partners LG Business Solutions at ATARC Federal Mobile Computing Summit , March ... provide education and examination into the mobility tools and technology employed by the ...
(Date:3/27/2017)... ... ... The Case Management Society of America (CMSA) will install six new members ... has elected their upcoming President-Elect, Secretary, Treasurer and two Directors to serve on the ... position has also been added to the BOD, per an appointment made by CMSA ...
(Date:3/27/2017)... ... March 27, 2017 , ... Advantexe ... announced the launch of a new research study, The Business Readiness Report. The ... execute that strategy, and the actual success of achieving individual and company goals. ...
(Date:3/27/2017)... ... ... is still in shock after receiving a $2,500 Academic Award from California Casualty . ... , She thinks the coming week is going to be a very joyful for her ... my students.” , The award will allow the 4th grade teacher at Tumwater Hill Elementary ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017  Twist Bioscience, a company accelerating science ... that it raised an additional $33 million. To date, ... "It is an exciting time to ... and continue to deliver industry-leading gene volume to our ... Emily M. Leproust, Ph.D., CEO of Twist Bioscience. "We ...
(Date:3/27/2017)... , March 27, 2017  PhaseRx, Inc. (NASDAQ: ... life-threatening inherited liver diseases in children, today reported ... year ended December 31, 2016 and provided an ... "PhaseRx continued to make progress during the fourth ... results from our non-human primate safety study, and with ...
(Date:3/27/2017)... , March 27, 2017 Invivotek, LLC, a ... in vivo pharmacology contract research organization (CRO), ... to its newly expanded preclinical research facility in ... provides a cleaner, renewable energy source to reduce costs ... Completion of the Genesis Solar Farm follows Invivotek,s recent ...
Breaking Medicine Technology: